VHFMoDRAD will develop and deliver rapid and point-of-care singel/multiplex diagnostic tool(s) that will significantly increase our capacity to handle outbreaks with Filoviruses and other viral hemorrhagic fever diseases in Africa. The overall aim of VHFMoDRAD is to carry on the outcome of the currently running EbolaMoDRAD project to the next level, which is behind of the scope of that project. The goals of VHFMoDRAD will be done via a multidisciplinary research consortium drawn from key European and African research organisations and also industry and SMEs, thus consolidating previous tools and knowledge. VHFMoDRAD will also put in place a strong capacity building programme in West Africa The project will disseminate widely all results as they become available, notably to public health bodies and non-governmental organisations (NGOs), via a strong outreach programme. To achieve this overall aim an intensive work plan will be put in place, with the following specific objectives: - to develop rapid molecular and serological single/multiplex detection methods; - perform preclinical validation of diagnostic tools; - to validate the successful diagnosis tools under field conditions; - implement a strong capacity building programme in West Africa by a twining program; - to exploit results; - to disseminate the results to public health bodies, NGOs, outbreak management teams and local hospitals in West Africa.

MEDIRAD aims to enhance the scientific bases and clinical practice of radiation protection (RP) in the medical field and thereby addresses the need to understand and evaluate the health effects of low dose ionising radiation exposure from diagnostic and therapeutic imaging and from off-target effects in radiotherapy (RT). MEDIRAD will pursue 3 major operational objectives: First, it will improve organ dose estimation and registration to inform clinical practice, optimise doses, set recommendations and provide adequate dosimetry for clinical-epidemiological studies of effects of medical radiation. Second, it aims to evaluate and understand the effects of medical exposures, focusing on the two major endpoints of public health relevance: cardiovascular effects of low to moderate doses of radiation from RT in breast cancer treatment incl. understanding of mechanisms; and long-term effects on cancer risk of low doses from CT in children. Third, it will develop science-based consensus policy recommendations for the effective protection of patients, workers and the general public. Within the 4-year project a multi-disciplinary consortium will, in close interaction with European medical associations, MELODI and EURADOS (1), develop a tool to determine image quality to maximise optimisation of RP in medical imaging, (2) improve and develop new individual organ/anatomical structure dosimetry from chest CT, I131 administration, fluoroscopy-guided procedures, hybrid imaging, and RT for breast cancer and interlinks with image quality measures, (3) conduct epidemiological studies of consequences of RT and CT, (4) identify potential novel imaging and circulating biomarkers and mechanisms of radiation effects, (5) develop innovative risk models, (6) develop and implement for the first time a European repository of patient dose and imaging data, (7) develop science-based recommendations, and (8) introduce novel approaches to bring together the nuclear and medical sectors.

This project (EICP) consists of 4 members, from Germany (Applicant organisation), Czech Republic, Croatia and Poland, who are key Europen stakeholders in Evidence-Based Healthcare (EBHC) in these countries. It is a combination of partners from universities who are focused on EBHC. The project members made initial contact thanks to the EVBRES Cost Action, Joanna Briggs Collaboration and Cochrane Collaboration which are not-for-profit organizations and European COST action and some project partners are members of this collaboration and COST Action.The EICP project was developed to address the needs of improving the skills and qualifications of European project partners in EBHC and critical thinking, especially in the implementation and utilization of evidence in healthcare clinical practice. The core idea of the project is to support cooperation and exchange of know-how within the unique Evidence Implementation Training Programme (EITP) context. Based on the current situation, there is not a completely established educational programme which is focused on evidence implementation into practice in Europe. This means that professionals in healthcare across Europe need to improve their experience and skills with the implementation of the research evidence into their practice. It is especially important in this era when praxis in some healthcare fields lags more than twenty years behind science. Critical thinking is a crucially important part of EHBC in our information era where is every year published in the PubMed, which is one of the relevant healthcare databases more than a million new publications yearly. The coordinator of this project from Germany is totally into the process of evidence-based research and Dissemination and implementation in different stakeholder groups, the Partner from Czech republic is one of the few institutions in Europe who has trainers qualified to deliver the unique EITP which was developed by experts from the Joanna Briggs Institute (JBI), Faculty of Health and Medical Sciences, University of Adelaide, Australia. JBI is a world leader in the field of EBHC towards evidence implementation, having developed the unique EITP.The key objective of this project is to decrease the gap between research and practice in healthcare and support international cooperation of professionals in healthcare. The project aims to support the development, transfer and implementation of innovative practice.The main direct impact of the project will be on the project participants enhancement of professional skills, enhancement of academics, social and economic benefits, and networking. The indirect impact will be provided by the Best Practice Implementation Projects (BPIPs), which have a significant potential to innovate current healthcare practice and thus to maintain the more effective and cost-effective practice, which will benefit patients/consumers and reduce the redundant economic burden of healthcare. To disseminate the project outcomes, a Dissemination plan will be implemented. The plan will comprise four different lines of actions: educational dissemination, clinical dissemination, online dissemination /internet/, and press and it will give clear measures and priorities of how to spread the findings and results elaborated by the project to the target public (local, regional, national, European and international). One of the important outcomes of the project will be to develop closer cooperation among European EBHC into strong European consortia, to disseminate and implement EBHC in terms of evidence implementation into practice.

Globally 1.Globally 1.71 billion people have musculoskeletal symptoms, the leading contributor to disability. Early disease stratification is important to ensure appropriate care (most suited healthcare provider and best treatment choice). Currently the patient journey to diagnosis and effective treatment is long and inefficient, resulting in persistent disease burden and economical loss. This is due to insufficiently understood relations disease causes and similarities in symptoms between diseases, insufficiently distinguishing tests, trial and error approach in initial treatment. SPIDeRR aims to disentangle the real-life complexity of early diagnosis of rheumatic diseases by considering the complete web of factors influencing patients’ symptoms. SPIDeRR’s approach will go well beyond the state-of-the-art in the following ways: - By identifying different disease groups, requiring different therapies, amongst patients with similar symptoms in contrast to the traditional approach aiming to only capture one disease early. - By integrating all relevant data dimensions from every healthcare level (primary and secondary care and patients seeking advice online). - By translating and applying machine learning techniques from the “omics” field to clinical patient data, which will result in new pipelines for translational data science SPIDERR will deliver three clinical models -a symptom checker for patients -a decision support tool for (primary) care providers providing guiding additional examination and referral decisions -a patient-patient similarity network to optimise diagnostic groups in rheumatology and support treatment decision To achieve this we additionally deliver solutions for data integration and shared analyses though GDPR compliant digital research environment and federated learning pipelines. Finally we will test the acceptability of the models through stakeholders studies and provide an implementation scene tailored to current healthcare in Europe.

The aim of VASCUL-AID is to predict the risk of cardiovascular events and progression of the vascular diseases Abdominal Aortic Aneurysm (AAA) and Peripheral Arterial Disease (PAD) to influence the course of disease improving the patient’s quality of life and care and assisting clinicians to make better-informed decisions involving the patient. VASCUL-AID will allow us for the first time to identify patients who are at high risk for AAA growth or PAD progression and cardiovascular events. To this end, we will deliver a clinically relevant and cost-effective trustworthy AI-driven platform (VASCUL-AID) that integrates multi-source parameters including imaging, proteomic and genomic data as well as life-style patient data from wearables to enable personalised vascular disease management. To maximise the personalised prevention strategies, VASCUL-AID leverages visualisation tools to improve clinician-patient communication and empower the patient. The VASCUL-AID platform consists of AI risk-prediction tools, a patient communication app an a clinical dashboard to support clinical decision-making. A particular emphasis is placed on ethics, to ensure beneficial implementation of AI prediction tools. In this project, we aim to (1) build an EU-wide data infrastructure, (2) develop an AI-based progression prediction tools for AAA and PAD, (3) develop criteria according to the COMET initiative to assess the effectiveness of VASCUL-AID, and (4) clinically test and show proof-of-concept for the VASCUL-AID platform. Once validated, this platform can be extended to other cardiovascular diseases (CVDs) as well. VASCUL-AID brings together 14 leading organisations (and 2 affiliated entities) consisting of clinical academic centres, institutes, universities and SMEs as well as large industry, patients organisations and policy makers that cover the full value chain to enable integration of the platform into clinical practice.